Active-targeting biomimetic nanosystem for prostate cancer enhances radiotherapy efficacy by inducing ferroptosis
- J Nanobiotechnology. 2025 Nov 30;24(1):9. doi: 10.1186/s12951-025-03879-w.
- 1. Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
- 2. Department of Urology, Daping Hospital, Army Medical University, Chongqing, 400042, China.
- 3. Department of Urology, Air Force 986 Hospital, Xi'an, 710054, China.
- 4. The Tenth Outpatient Department, Air Force 986 Hospital, Xi'an, 710054, China.
- 5. Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China.
- 6. Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, China. [email protected].
- 7. Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. [email protected].
- 8. Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. [email protected].
Radioresistance and off-target toxicity remain major challenges in prostate Cancer (PCa) radiotherapy. Here, we report a biomimetic nanoplatform (Au/MOF-FIN@M-gy1) that synergistically enhances radiation deposition and Ferroptosis for precision radiosensitization. By engineering macrophage membranes with prostate-specific membrane antigen (PSMA)-targeting nanobodies (gy1), we achieve tumor-selective delivery of Au/MOF nanoparticles preloaded with Ferroptosis inducers (FINs). Upon lysosomal release, FINs disrupt redox homeostasis via GPX4 suppression, while Au/MOF amplifies radiation-induced Reactive Oxygen Species (ROS), collectively triggering lethal lipid peroxidation cascades. This dual mechanism is further demonstrated to elicit radiosensitizing effects in both bone-metastatic and radio-refractory PCa models without requiring radiation dose escalation, thereby improving the therapeutic index. Our study demonstrates a nanoparticle-enabled strategy to enhance tumor-specific radiotherapy by dual-targeting metabolic vulnerabilities.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer